aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
TandemAI was founded with the mission to revolutionize the drug discovery process through advanced artificial intelligence and physics-based platforms. The company aims to integrate innovative technologies into traditional workflows, thereby accelerating the discovery and development of new drugs. Their flagship product, TandemViz, empowers research teams by providing a comprehensive, integrated platform for drug discovery. TandemAI focuses on leveraging AI to streamline and enhance the efficiency of pharmaceutical research and development.
Notable figures affiliated with TandemAI include leading experts in AI and drug discovery, though specific names are not publicly highlighted. The company has garnered attention through significant media coverage and industry events, such as webinars on AI and computational tools. TandemAI's key achievements include the successful integration of their AI platform into existing drug discovery processes, significantly reducing time and costs associated with bringing new drugs to market. Their impact is marked by a transformative approach that promises to redefine the future of pharmaceutical research.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Drug Discovery
Technology
AI
Tags
Biotech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was TandemAI founded?
TandemAI was founded in 2021.
Where is TandemAI's headquarters located?
TandemAI's headquarters is located in New York City, NY, US.
When was TandemAI's last funding round?
TandemAI's most recent funding round was for $35M (USD) in March 2023.
How many employees does TandemAI have?
TandemAI has 46 employees as of Feb 4, 2024.
How much has TandemAI raised to-date?
As of July 05, 2023, TandemAI has raised a total of $60M (USD) since Mar 1, 2023.
Add Comparison
Total Raised to Date
$60M
USD
Last Update Mar 1, 2023
Last Deal Details
$35M
USD
Mar 1, 2023
Series A
Total Employees Over Time
46
As of Feb 2024
TandemAI Address
36 E 12th St
Fl 2nd
New York City,
New York
10003
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts